Molecular Aberrations Stratify Grade 2 Astrocytomas Into Several Rare Entities: Prognostic and Therapeutic Implications

Valeria Internò; Giacomo Triggiano; Pierluigi De Santis; Luigia Stefania Stucci; Marco Tucci; Camillo Porta

doi:10.3389/fonc.2022.866623

Molecular Aberrations Stratify Grade 2 Astrocytomas Into Several Rare Entities: Prognostic and Therapeutic Implications

Front Oncol. 2022 Jun 10:12:866623. doi: 10.3389/fonc.2022.866623. eCollection 2022.

Authors

Valeria Internò^{1

2}, Giacomo Triggiano², Pierluigi De Santis², Luigia Stefania Stucci², Marco Tucci^{1

2}, Camillo Porta^{1

2}

Affiliations

¹ Department of Interdisciplinary Medicine, University of Bari 'Aldo Moro', Bari, Italy.
² Division of Medical Oncology, Policlinico Hospital of Bari, Bari, Italy.

Abstract

The identification of specific molecular aberrations guides the prognostic stratification and management of grade 2 astrocytomas. Mutations in isocitrate dehydrogenase (IDH) 1 and 2, found in the majority of adult diffuse low-grade glioma (DLGG), seem to relate to a favorable prognosis compared to IDH wild-type (IDH-wt) counterparts. Moreover, the IDH-wt group can develop additional molecular alterations worsening the prognosis, such as epidermal growth factor receptor amplification (EGFR-amp) and mutation of the promoter of telomerase reverse transcriptase (pTERT-mut). This review analyzes the prognostic impact and therapeutic implications of genetic alterations in adult LGG.

Keywords: EGFR amplification; IDH-wt grade 2 astrocytoma; diffuse low-grade gliomas; pTERT mutation; prognostic molecular stratification.

Publication types

Review